AUTHOR=Yang Minghua , Wang Haoyang , Bukhari Ihtisham , Zhao Ye , Huang Huang , Yu Yong , Sun Xiangdong , Mi Yang , Mei Lu , Zheng Pengyuan 

TITLE=Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice

JOURNAL=Frontiers in Nutrition

VOLUME=10

YEAR=2023

URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1121203

DOI=10.3389/fnut.2023.1121203

ISSN=2296-861X

ABSTRACT=<sec><title>Background/aims</title><p>Some studies showed that probiotics could improve the composition and structure of gut microbiota. Changes in the gut microbiota may alter bile acid (BAs) composition and kinetics, improving non-alcoholic fatty liver disease (NAFLD). However, it still needs to be clarified how probiotics improve both the metabolism of BAs and NAFLD. This study aimed to reveal the regulatory mechanisms of cholesterol-lowering (CL) probiotics on NAFLD from aspects involved in BA metabolism in FXR gene knockout (FXR<sup>−/−</sup>) mice.</p></sec><sec><title>Methods</title><p>FXR<sup>−/−</sup> male mice were randomly divided into three groups based on different interventions for 16 weeks, including normal diet (ND), high-fat diet (HFD), and probiotic intervention in the HFD (HFD+P) group. 16s rDNA sequencing and ultrahigh performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) were utilized to analyze the changes in gut microbiota and fecal bile acids in mice.</p></sec><sec><title>Results</title><p>We found that the intervention of the CL probiotics improved liver lipid deposition and function in HFD-induced NAFLD mice by decreasing the levels of total cholesterol (TC; <italic>p</italic> = 0.002) and triglyceride (TG; <italic>p</italic> = 0.001) in serum, as well as suppressing liver inflammation, such as interleukin-1 beta (IL-1β; <italic>p</italic> = 0.002) and tumor necrosis factor-alpha (TNF-α; <italic>p</italic> &lt; 0.0001). 16S rDNA sequencing and metabolomic analyses showed that probiotics effectively reduced the abundance of harmful gut microbiota, such as Firmicutes (<italic>p</italic> = 0.005), while concomitantly increasing the abundance of beneficial gut microbiota in NAFLD mice, such as Actinobacteriota (<italic>p</italic> = 0.378), to improve NAFLD. Compared with the ND group, consuming an HFD elevated the levels of total BAs (<italic>p</italic> = 0.0002), primary BAs (<italic>p</italic> = 0.017), and secondary BAs (<italic>p</italic> = 0.0001) in mice feces, while the intervention with probiotics significantly reduced the increase in the levels of fecal total bile acids (<italic>p</italic> = 0.013) and secondary bile acids (<italic>p</italic> = 0.017) induced by HFD.</p></sec><sec><title>Conclusion</title><p>The CL probiotics were found to improve liver function, restore microbiota balance, correct an abnormal change in the composition and content of fecal bile acids, and repair the damaged intestinal mucosal barrier in mice with NAFLD, ultimately ameliorating the condition. These results suggested that CL probiotics may be a promising and health-friendly treatment option for NAFLD.</p></sec>